Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma PLC (~292)

  Print      Mail a friend       Annual reports

Monday 22 March, 2004

Antisoma PLC

R&D Update

Antisoma PLC
22 March 2004

                            Antisoma plc R&D update
                      AS1404 advancing to phase II trials
                 AS1405 starts clinical trials in brain cancer

London UK, 22 March 2004 - Antisoma plc (LSE: ASM), the biopharmaceutical
company specialising in the development of novel anti-cancer drugs, will today
hold an R&D update for analysts and investors. This will focus on a number of
the Company's earlier stage clinical and preclinical products.

Announced today
Two of the drugs covered in today's update are the subject of significant
progress announcements. AS1404 (DMXAA) has completed phase I studies and will
now move into phase II, while AS1405 (formerly AngioMab) has begun its first
phase I clinical trial. Though their actions are different, both drugs attack
cancer by targeting tumour blood vessels.

The third and final phase I study of AS1404 as a monotherapy has been
successfully completed. This has provided data required to plan a phase II
programme of combination studies, which is scheduled to start during the second
half of 2004. AS1404 is considered most likely to provide a benefit when used
alongside other therapies. Separate trials will be conducted in different tumour
types, each combining AS1404 with an established cancer treatment. In at least
one of the trials AS1404 will be given with taxane drugs because this
combination has shown particular promise in preclinical work. AS1404 belongs to
a class of drugs called 'vascular targeting agents' which specifically disrupt
tumour blood vessels. The drug therefore has potential against a wide variety of

AS1405 has started its first trial in patients with a highly malignant brain
cancer called glioma. The phase I trial will provide information on safety,
dosing and distribution of the drug, as well as looking for any initial signs of
anti-tumour activity. Patients included in the study have suffered a relapse of
their glioma with regrowth of the tumour after their initial treatment. The
majority of the new tumour growth will be removed by surgery followed by an
injection of AS1405 into the cavity left in the brain. AS1405 is a radiolabelled
antibody that binds to a protein found around new tumour blood vessels. It
delivers a targeted dose of radiation with the aim of preventing or delaying the
relapse of cancer.

Because glioma is a relatively rare cancer, a so-called 'niche indication',
AS1405 is not included in Antisoma's alliance with Roche.  Antisoma intends to
pursue alternative routes to commercialisation, with the intention to maximise
its retained share of the product's value. Given the very poor results with
current treatments, Antisoma considers this an attractive opportunity. The
Company estimates that on the basis of the need for a suitable surgical history,
and taking together newly diagnosed patients and those with recurrent disease,
some 29,000 patients could be eligible for the treatment each year in North
America, Europe and Japan.

R&D update overview
Three external experts will speak on the background to Antisoma's AS1404, AS1405
and telomerase inhibitor programmes.

The background to vascular targeting agents, the class of drugs to which AS1404
belongs, will be provided by Prof Richard Begent of the Royal Free and
University College Medical School, UCL. He will consider the variety of ways to
attack tumour blood vessels and how drugs of this type can be combined with
other cancer treatments to maximise their effect.

Prof David Thomas, a neurosurgeon from The National Hospital for Neurology and
Neurosurgery in London, will talk about the issues in treating brain cancers.
Speaking in advance of the meeting, Prof Thomas said: 'Brain cancer is a huge
challenge; we can often operate to remove the bulk of the cancer, but we need
drugs that can be used alongside surgery to attack the cancer that we can't get
out. There's a lot of interest at the moment in targeted approaches such as the
use of monoclonal antibodies.'

Professor Stephen Neidle of the London School of Pharmacy will describe the
anti-cancer drugs known as telomerase inhibitors. He developed the programme of
telomerase inhibitors that Antisoma in-licensed from Cancer Research UK during

In addition to the external speakers, Dr Nigel Courtenay Luck, Chief Scientific
Officer of Antsioma, will highlight the broad potential of antibodies in cancer
treatment, illustrated by the ways in which Antisoma is adapting its antibodies
for use in different settings. These include development of naked antibody drugs
like R1550, radiolabelling approaches as used in R1549 and AS1405, linking of
apoptosis enzymes as in AS1406, and most recently the use of antibodies in
conjunction with cytokines, illustrated by the ATTACK programme under
co-development with EMD Lexigen Research Center of the US.

Speaking before the R&D update, Glyn Edwards, Antisoma's Chief Executive Officer
commented: 'The advances we have announced today for AS1404 and AS1405 show the
steady progress we are making in developing and broadening our clinical
pipeline. Today's event will also highlight the strong scientific foundations on
which our programmes and collaborations are based.'

Glyn Edwards, Chief Executive Officer                   Tel: +44 (0)20 8799 8200

Ben Atwell/Julia Phillips, Financial Dynamics           Tel: +44 (0)20 7831 3113

About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. Please visit
for further information about Antisoma.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                 

a d v e r t i s e m e n t